Mithra Pharmaceuticals SA

Symbol: MITRA.BR

EURONEXT

0.226

EUR

Market price today

  • -0.0900

    P/E Ratio

  • 0.0003

    PEG Ratio

  • 15.62M

    MRK Cap

  • 0.00%

    DIV Yield

Mithra Pharmaceuticals SA (MITRA-BR) Financial Statements

On the chart you can see the default numbers in dynamics for Mithra Pharmaceuticals SA (MITRA.BR). Companys revenue shows the average of 34.971 M which is 0.349 % gowth. The average gross profit for the whole period is 21.36 M which is 0.881 %. The average gross profit ratio is 0.451 %. The net income growth for the company last year performance is 1.910 % which equals -1.126 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Mithra Pharmaceuticals SA, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.352. In the realm of current assets, MITRA.BR clocks in at 93.408 in the reporting currency. A significant portion of these assets, precisely 8.98, is held in cash and short-term investments. This segment shows a change of -0.683% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 16.194, if any, in the reporting currency. This indicates a difference of -33.421% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 147.53 in the reporting currency. This figure signifies a year_over_year change of -0.099%. Shareholder value, as depicted by the total shareholder equity, is valued at -103.255 in the reporting currency. The year over year change in this aspect is -4.065%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 36.092, with an inventory valuation of 48.29, and goodwill valued at 5.23, if any. The total intangible assets, if present, are valued at 0. Account payables and short-term debt are 59.07 and 26.7, respectively. The total debt is 205.86, with a net debt of 196.88. Other current liabilities amount to 15.7, adding to the total liabilities of 389.8. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012

balance-sheet.row.cash-and-short-term-investments

90.28928.332.9
138.7
49.8
118.9
36.2
45.8
96.8
1.7
1.6
0.7

balance-sheet.row.short-term-investments

0000
0
0
0
0
43.6
89
0
0
0

balance-sheet.row.net-receivables

142.5636.162.620.3
60
25.5
5.2
25.4
3.5
6
2.7
3.6
2.5

balance-sheet.row.inventory

196.2648.350.343.9
35.4
16.3
10.9
4.1
4.2
2.8
1.8
2.4
2.4

balance-sheet.row.other-current-assets

4.9204.72.4
4.4
3
8.3
8.5
4.4
3.5
2.1
0.5
0.7

balance-sheet.row.total-current-assets

434.0193.4145.999.4
238.5
91.5
143.4
74.2
57.9
109.1
8.2
8.1
6.3

balance-sheet.row.property-plant-equipment-net

367.1951.5106.3107.7
99.5
94
84.4
59.5
17
3.6
2.4
1.5
1.1

balance-sheet.row.goodwill

20.935.25.25.2
5.2
5.2
5.2
5.2
5.2
8
3.8
0
0

balance-sheet.row.intangible-assets

402.020140.1110.2
94.2
92.7
78.8
78.8
79.1
78.2
2.2
1.7
1.9

balance-sheet.row.goodwill-and-intangible-assets

422.955.2145.4115.4
99.5
98
84
84
84.4
86.3
2.2
1.7
1.9

balance-sheet.row.long-term-investments

82.5416.224.332
32.7
80.1
14.6
0.2
0.2
0.2
2.1
0.2
0

balance-sheet.row.tax-assets

98.181.316.463.5
50.9
34.4
27
22.7
12.2
5.3
0.6
0.2
0.4

balance-sheet.row.other-non-current-assets

131.32118.94.34
0.9
-0.4
-41.6
-22.9
-12.2
-5.3
-0.6
0.2
0.1

balance-sheet.row.total-non-current-assets

1102.19193.1296.6322.5
283.5
306.1
168.4
143.6
101.5
90
6.7
3.8
3.4

balance-sheet.row.other-assets

0000
0
0
47.9
26.9
13.3
6.5
0.8
0
0

balance-sheet.row.total-assets

1536.2286.5442.4421.9
522
397.6
359.7
244.7
172.7
205.6
15.7
11.9
9.6

balance-sheet.row.account-payables

163.0759.131.716.9
23.3
19.4
13.1
16.1
9.3
4.6
3.5
2.6
1.4

balance-sheet.row.short-term-debt

160.6126.752.453.1
18.8
13.3
20.3
15.7
7
17.9
23.2
3.4
3.6

balance-sheet.row.tax-payables

0000
0
0.1
0.3
0
0.1
0
0.3
1.2
0.4

balance-sheet.row.long-term-debt-total

557.28147.5137.8125.2
124.5
19.1
118.2
69.2
48.2
37.7
1.6
1.2
1.3

Deferred Revenue Non Current

56.5417.98.112.8
18.9
17.1
4
0.5
8.3
8.5
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

14.34---
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

120.0315.744.924.1
27.4
14.3
23
20.3
11.4
11.4
-18.2
2.1
0

balance-sheet.row.total-non-current-liabilities

1127.49285.8278.3292.3
293.5
186.5
118.2
69.2
48.2
37.7
1.6
1.2
1.3

balance-sheet.row.other-liabilities

0000
0
0
54.5
36.4
3.7
6
0
0
0

balance-sheet.row.capital-lease-obligations

144.2531.638.342.4
44.3
45.7
48
34.1
0
0
0
0
0

balance-sheet.row.total-liab

1578.38389.8408.7388.1
364.2
234.3
208.8
157.8
79.7
78.2
10.2
9.4
7.6

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

171.7450.641.232.3
31.3
28.6
26.9
25
22.6
22.6
3.1
5
2.5

balance-sheet.row.retained-earnings

-1818.19-589.3-396.3-336.6
-219.8
-127.7
-101.1
-88.7
-53.7
-18.6
-8.2
-2.6
-0.5

balance-sheet.row.accumulated-other-comprehensive-income-loss

-27.4510.6-19.9-2.5
13.7
3.4
1.3
2.3
1.3
0.6
0
-0.7
-0.5

balance-sheet.row.other-total-stockholders-equity

1631.73424.9408.6340.8
332.5
258.9
223.8
148.3
122.8
122.8
10.6
0.7
0.5

balance-sheet.row.total-stockholders-equity

-42.17-103.333.733.8
157.7
163.3
150.9
86.9
93
127.4
5.5
2.5
2

balance-sheet.row.total-liabilities-and-stockholders-equity

1536.2286.5442.4421.9
522
397.6
359.7
244.7
172.7
205.6
61
11.9
9.6

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

-42.17-103.333.733.8
157.7
163.3
150.9
86.9
93
127.4
5.5
2.5
2

balance-sheet.row.total-liabilities-and-total-equity

1536.2---
-
-
-
-
-
-
-
-
-

Total Investments

82.5416.224.332
32.7
80.1
14.6
0.2
43.8
89.2
2.1
0.2
0

balance-sheet.row.total-debt

862.15205.9228.4220.7
187.6
78.1
186.5
111.2
55.2
55.5
49.8
4.7
4.9

balance-sheet.row.net-debt

771.87196.9200.1187.8
48.9
28.3
67.5
75
53
47.8
48.1
3.1
4.2

Cash Flow Statement

The financial landscape of Mithra Pharmaceuticals SA has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.976. The company recently extended its share capital by issuing 0, marking a difference of 22.718 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 0 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to 3452000.000 in the reporting currency. This is a shift of -1.135 from the previous year. In the same period, the company recorded 12.21, 0, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 0, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012

cash-flows.row.net-income

-233.12-173.5-59.6-116.9
-92.1
-26.6
-12.4
-35
-35.1
-9.8
-3
-0.6
0.2

cash-flows.row.depreciation-and-amortization

24.1512.211.910.4
9.9
5.8
2.7
2
0.9
0.7
0.7
0.6
0.5

cash-flows.row.deferred-income-tax

-17.110-57-15.8
-38.5
-69.4
-3.7
24.9
-0.9
5.5
0
0
0

cash-flows.row.stock-based-compensation

1.36021.1
7.3
4.9
1.2
1
0.7
0.6
0
0
0

cash-flows.row.change-in-working-capital

20.440-31.16.2
-11.5
-53
2.5
-25.9
0.2
-6.1
1.4
0.5
0.6

cash-flows.row.account-receivables

19.610-42.516.7
7.1
-59
10.1
-25.9
1.5
-5
0.8
-1
0

cash-flows.row.inventory

-5.680-6.9-8.5
-19.1
-5.3
-7.6
0
-1.4
-1
0.7
0
0.1

cash-flows.row.account-payables

6.52018.2-2
0.5
11.3
-9.1
8.5
11.7
-1.5
0
1
0

cash-flows.row.other-working-capital

0000
0
0
9.1
-8.5
-11.7
0
0
1.5
0.5

cash-flows.row.other-non-cash-items

135.41159.167.128.8
41.3
88.2
13.2
26.8
9.9
-3.5
0.1
0
-0.5

cash-flows.row.net-cash-provided-by-operating-activities

-68.86000
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-31.260-25.7-21.2
-16.2
-15.5
-10
-14.8
-13.8
-2.2
-1.3
-0.8
-0.4

cash-flows.row.acquisitions-net

0.1700.20
0
0
19.4
0.3
-8.5
-18
-2
-0.3
0

cash-flows.row.purchases-of-investments

0000
0
0
0
0
0
-1.9
0
-0.2
0

cash-flows.row.sales-maturities-of-investments

10.21000
0
0
0
0
8.5
19.9
2
-0.1
0

cash-flows.row.other-investing-activites

-2.2500-33.5
0
-5
-3.8
-1.3
-3.6
-11.5
-5.2
0.1
0

cash-flows.row.net-cash-used-for-investing-activites

-22.043.5-25.5-54.7
-16.2
-20.5
5.6
-15.7
-25.8
-33.6
-8.5
-1.3
-0.4

cash-flows.row.debt-repayment

-60.670-45.4-33.8
-0.9
-4.1
-1.4
-0.6
-17.1
-3.5
-0.2
-0.6
-0.6

cash-flows.row.common-stock-issued

52.540509.2
188.1
0.2
75.2
27.9
0
131
11.2
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
-11
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
-2.2
-0.6
0

cash-flows.row.other-financing-activites

40.61083.159.6
1.4
5.3
-0.2
9.9
15.4
19.2
0.5
2.7
0.6

cash-flows.row.net-cash-used-provided-by-financing-activities

67.19-20.587.735
188.7
1.4
73.7
37.2
-1.8
146.7
9.3
1.6
0

cash-flows.row.effect-of-forex-changes-on-cash

-0.180-0.10
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-23.89-19.3-4.6-105.8
89
-69.2
82.8
-9.6
-51
95.1
0.1
0.9
0.5

cash-flows.row.cash-at-end-of-period

90.28928.332.9
138.7
49.7
118.9
36.2
45.8
96.8
1.7
1.6
0.7

cash-flows.row.cash-at-beginning-of-period

114.1728.332.9138.7
49.7
118.9
36.2
45.8
96.8
1.7
1.6
0.7
0.2

cash-flows.row.operating-cash-flow

-68.86-2.2-66.7-86.2
-83.5
-50.1
3.5
-31.1
-23.4
-18.1
-0.7
0.5
0.9

cash-flows.row.capital-expenditure

-31.260-25.7-21.2
-16.2
-15.5
-10
-14.8
-13.8
-2.2
-1.3
-0.8
-0.4

cash-flows.row.free-cash-flow

-100.12-2.2-92.3-107.3
-99.8
-65.6
-6.5
-45.9
-37.2
-20.3
-2
-0.3
0.5

Income Statement Row

Mithra Pharmaceuticals SA's revenue saw a change of -0.401% compared with the previous period. The gross profit of MITRA.BR is reported to be 5.99. The company's operating expenses are 75.31, showing a change of 9.344% from the last year. The expenses for depreciation and amortization are 12.21, which is a 0.023% change from the last accounting period. Operating expenses are reported to be 75.31, which shows a 9.344% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -1.073% year-over-year growth. The operating income is -69.32, which shows a 1.073% change when compared to the previous year. The change in the net income is 1.910%. The net income for the last year was -173.5.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012

income-statement-row.row.total-revenue

107.1540.26722.7
9
96.5
57.9
32
22.5
20.4
19
17.7
14.8

income-statement-row.row.cost-of-revenue

65.7334.231.626.1
13.3
8.3
1.6
2.6
9
10.2
10
9.1
7.4

income-statement-row.row.gross-profit

41.42635.4-3.5
-4.3
88.3
56.3
29.4
13.4
10.2
9.1
8.6
7.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

127.71---
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

21.87---
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

3.29---
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0028.30
0
-0.2
-46.5
0
0
0
0
0
-0.1

income-statement-row.row.operating-expenses

144.6975.368.989.2
86
67.8
90.3
79.3
54
24.5
12.1
9.2
7.1

income-statement-row.row.cost-and-expenses

210.41109.5100.4115.4
99.3
76.1
91.9
81.8
63
34.7
22.1
18.2
14.5

income-statement-row.row.interest-income

7.921.71411.8
3.5
3.3
3.5
1.7
0.1
0.3
0.2
0.1
0

income-statement-row.row.interest-expense

46.3222.91712.1
3.6
3.4
5.4
0.3
1.3
0.8
1.2
0.1
0.2

income-statement-row.row.selling-and-marketing-expenses

3.29---
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-72.59-92.519.9-33.7
-22.5
-53.4
-51.7
-25.3
-4.7
-0.3
-0.3
-0.2
-0.2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0028.30
0
-0.2
-46.5
0
0
0
0
0
-0.1

income-statement-row.row.total-operating-expenses

-72.59-92.519.9-33.7
-22.5
-53.4
-51.7
-25.3
-4.7
-0.3
-0.3
-0.2
-0.2

income-statement-row.row.interest-expense

46.3222.91712.1
3.6
3.4
5.4
0.3
1.3
0.8
1.2
0.1
0.2

income-statement-row.row.depreciation-and-amortization

24.1512.211.910.4
9.9
5.8
2.7
2
0.9
0.7
0.7
0.6
0.5

income-statement-row.row.ebitda-caps

-79.11---
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-103.26-69.3-33.4-92.7
-90.3
20.4
14.2
-26.2
-36
-14.3
-2.9
-0.6
0.2

income-statement-row.row.income-before-tax

-175.86-161.8-13.6-126.3
-112.8
-33
-37.5
-51.5
-40.6
-14.6
-3.2
-0.8
0.1

income-statement-row.row.income-tax-expense

57.2711.746.1-9.5
-20.7
-6.4
9.9
13.1
5.5
4.8
0.3
0.8
0.7

income-statement-row.row.net-income

-233.12-173.5-59.6-116.9
-92.1
-26.6
-27.6
-38.4
-35.1
-9.8
-3
-1.5
-0.6

Frequently Asked Question

What is Mithra Pharmaceuticals SA (MITRA.BR) total assets?

Mithra Pharmaceuticals SA (MITRA.BR) total assets is 286546000.000.

What is enterprise annual revenue?

The annual revenue is 40154999.000.

What is firm profit margin?

Firm profit margin is 0.149.

What is company free cash flow?

The free cash flow is -0.113.

What is enterprise net profit margin?

The net profit margin is -4.321.

What is firm total revenue?

The total revenue is -1.739.

What is Mithra Pharmaceuticals SA (MITRA.BR) net profit (net income)?

The net profit (net income) is -173502000.000.

What is firm total debt?

The total debt is 205864000.000.

What is operating expences number?

The operating expences are 75312000.000.

What is company cash figure?

Enretprise cash is 8980000.000.